|
AU580145B2
(en)
|
1985-02-13 |
1989-01-05 |
Scios Nova Inc. |
Human metallothionein-ii promoter in mammalian expression system
|
|
US4902505A
(en)
|
1986-07-30 |
1990-02-20 |
Alkermes |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
|
US4987071A
(en)
|
1986-12-03 |
1991-01-22 |
University Patents, Inc. |
RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
|
|
US4904582A
(en)
|
1987-06-11 |
1990-02-27 |
Synthetic Genetics |
Novel amphiphilic nucleic acid conjugates
|
|
US5176996A
(en)
|
1988-12-20 |
1993-01-05 |
Baylor College Of Medicine |
Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
|
|
US5256775A
(en)
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
|
US5264564A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences |
Oligonucleotide analogs with novel linkages
|
|
AU734051B2
(en)
|
1996-04-05 |
2001-05-31 |
Salk Institute For Biological Studies, The |
Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
|
DE69740107D1
(de)
|
1996-12-23 |
2011-03-10 |
Immunex Corp |
Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
|
|
US6316408B1
(en)
|
1997-04-16 |
2001-11-13 |
Amgen Inc. |
Methods of use for osetoprotegerin binding protein receptors
|
|
US6274338B1
(en)
|
1998-02-24 |
2001-08-14 |
President And Fellows Of Harvard College |
Human c-Maf compositions and methods of use thereof
|
|
US6355623B2
(en)
|
1998-09-24 |
2002-03-12 |
Hopital-Sainte-Justine |
Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
|
|
DE60021254T2
(de)
|
1999-03-15 |
2006-04-20 |
AXYS Pharmaceuticals, Inc., South San Francisco |
N-cyanomethylamide als protease inhibitoren
|
|
TW404030B
(en)
|
1999-04-12 |
2000-09-01 |
Siliconware Precision Industries Co Ltd |
Dual-chip semiconductor package device having malposition and the manufacture method thereof
|
|
US6287813B1
(en)
|
1999-04-23 |
2001-09-11 |
Cistronics Cell Technology Gmbh |
Antibiotic-based gene regulation system
|
|
DE60132975T2
(de)
|
2000-01-06 |
2009-02-26 |
Merck Frosst Canada Inc., Kirkland |
Neue substanzen und verbindungen als protease-inhibitoren
|
|
HUP0204139A3
(en)
*
|
2000-02-16 |
2003-07-28 |
Yamanouchi Pharma Co Ltd |
Use of n-[6-methoxi-5-(2-methoxiphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2phenyl-etienesulfonamide for producing pharmaceutical composition using for reducing pain in an endothelin-induced disease
|
|
US6750015B2
(en)
|
2000-06-28 |
2004-06-15 |
Kathryn B. Horwitz |
Progesterone receptor-regulated gene expression and methods related thereto
|
|
EP2295081B1
(en)
|
2001-06-26 |
2018-10-31 |
Amgen Inc. |
Antibodies to OPGL
|
|
AR036375A1
(es)
|
2001-08-30 |
2004-09-01 |
Novartis Ag |
Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
|
|
GB0121033D0
(en)
|
2001-08-30 |
2001-10-24 |
Novartis Ag |
Organic compounds
|
|
KR100485271B1
(ko)
|
2002-01-16 |
2005-04-27 |
메타볼랩(주) |
전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물
|
|
SE0201980D0
(sv)
|
2002-06-24 |
2002-06-24 |
Astrazeneca Ab |
Novel compounds
|
|
DE10235624A1
(de)
|
2002-08-02 |
2004-02-19 |
Aventis Pharma Deutschland Gmbh |
Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben
|
|
US20050060771A1
(en)
|
2003-09-11 |
2005-03-17 |
Farmer Andrew Alan |
siRNA encoding constructs and methods for using the same
|
|
WO2005046731A1
(en)
|
2003-10-17 |
2005-05-26 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Interference with c-maf function in multiple myeloma
|
|
JP4579581B2
(ja)
|
2003-12-08 |
2010-11-10 |
株式会社グリーンペプタイド |
副甲状腺ホルモン関連タンパク質のｈｌａ−ａ２４またはｈｌａ−ａ２結合ペプチド
|
|
WO2005060722A2
(en)
|
2003-12-18 |
2005-07-07 |
President And Fellows Of Hardvard College |
Modulation of immune system function by modulation of polypeptide arginine methyltransferases
|
|
TW200526224A
(en)
|
2003-12-22 |
2005-08-16 |
Alcon Inc |
Short form c-Maf transcription factor antagonists for treatment of glaucoma
|
|
JP2007524671A
(ja)
*
|
2004-01-21 |
2007-08-30 |
カイロン コーポレイション |
Ｍ−ｃｓｆムテインおよびその使用
|
|
WO2005116056A1
(ja)
|
2004-05-26 |
2005-12-08 |
Green Peptide Co., Ltd. |
副甲状腺ホルモン関連タンパク質のhla-a24またはhla-a2結合ペプチド
|
|
US20080131940A1
(en)
|
2004-06-25 |
2008-06-05 |
Robert Chiu |
Target Cell-Specific Short Interfering Rna and Methods of Use Thereof
|
|
WO2006135436A2
(en)
|
2004-10-22 |
2006-12-21 |
University Of Florida Research Foundation, Inc. |
Inhibition of gene expression and therapeutic uses thereof
|
|
CA2623405C
(en)
|
2005-09-20 |
2014-11-25 |
Immunivest Corporation |
Methods and composition to generate unique sequence dna probes labeling of dna probes and the use of these probes
|
|
US9134237B2
(en)
|
2005-09-20 |
2015-09-15 |
Janssen Diagnotics, LLC |
High sensitivity multiparameter method for rare event analysis in a biological sample
|
|
EP1969000A2
(en)
|
2005-12-06 |
2008-09-17 |
Centre National de la Recherche Scientifique |
Cell penetrating peptides for intracellular delivery of molecules
|
|
US8080384B2
(en)
*
|
2006-04-05 |
2011-12-20 |
Yokohama City University |
Method for determination of prognosis of prostate cancer, and diagnostic agent for use in the method
|
|
WO2008098351A1
(en)
|
2007-02-14 |
2008-08-21 |
University Health Network |
Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
|
|
EP1961825A1
(en)
*
|
2007-02-26 |
2008-08-27 |
INSERM (Institut National de la Santé et de la Recherche Medicale) |
Method for predicting the occurrence of metastasis in breast cancer patients
|
|
CA2687903C
(en)
|
2007-05-24 |
2016-09-13 |
Ablynx N.V. |
Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
|
|
WO2009049410A1
(en)
|
2007-10-18 |
2009-04-23 |
University Health Network |
Clioquinol for the treatment of hematological malignancies
|
|
WO2009146546A1
(en)
|
2008-06-06 |
2009-12-10 |
University Health Network |
8-hydroxyquinoline derivatives for the treatment of hematological malignancies
|
|
CA2751854A1
(en)
*
|
2009-02-25 |
2010-09-02 |
Merrion Research Iii Limited |
Composition and drug delivery of bisphosphonates
|
|
EP3517630B1
(en)
|
2010-10-06 |
2022-01-19 |
Institució Catalana de Recerca i Estudis Avançats |
Method for the diagnosis, prognosis and treatment of breast cancer metastasis
|
|
ES2379918B1
(es)
|
2010-10-06 |
2013-05-10 |
Fundació Privada Institut De Recerca Biomèdica |
Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama.
|
|
US20140162887A1
(en)
|
2011-02-04 |
2014-06-12 |
Bioarray Therapeutics, Inc. |
Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
|
|
EP2678448A4
(en)
|
2011-02-22 |
2014-10-01 |
Caris Life Sciences Luxembourg Holdings S A R L |
CIRCULATING BIOMARKERS
|
|
EP2650682A1
(en)
|
2012-04-09 |
2013-10-16 |
Fundació Privada Institut de Recerca Biomèdica |
Method for the prognosis and treatment of cancer metastasis
|
|
EP3467124A1
(en)
|
2012-06-06 |
2019-04-10 |
Fundació Institut de Recerca Biomèdica IRB (Barcelona) |
Method for the diagnosis, prognosis and treatment of lung cancer metastasis
|
|
US10119171B2
(en)
|
2012-10-12 |
2018-11-06 |
Inbiomotion S.L. |
Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
|
|
KR101872965B1
(ko)
*
|
2012-10-12 |
2018-06-29 |
인바이오모션 에스.엘. |
Ｃ―ｍａｆ를 이용하는 전립선암 전이의 진단, 예후 및 치료 방법
|
|
CA2903306A1
(en)
|
2013-03-15 |
2014-09-18 |
Fundacio Institut De Recerca Biomedica (Irb Barcelona) |
Method for the diagnosis, prognosis and treatment of metastatic cancer
|
|
WO2014184679A2
(en)
|
2013-03-15 |
2014-11-20 |
Inbiomotion S.L. |
Method for the prognosis and treatment of renal cell carcinoma metastasis
|
|
JP6577873B2
(ja)
|
2013-03-15 |
2019-09-18 |
フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） |
がんの転移の予後診断および処置のための方法
|
|
TR201907389T4
(tr)
|
2013-10-09 |
2019-06-21 |
Fundacio Inst De Recerca Biomedica Irb Barcelona |
Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
|
|
US11129851B2
(en)
|
2014-06-17 |
2021-09-28 |
Igenomix S.L. |
Stem cell therapy in endometrial pathologies
|
|
KR20170093182A
(ko)
|
2014-12-11 |
2017-08-14 |
인바이오모션 에스.엘. |
인간 c-maf에 대한 결합 구성원
|
|
AU2017271385B2
(en)
|
2016-05-25 |
2023-10-05 |
Inbiomotion S.L. |
Therapeutic treatment of breast cancer based on c-MAF status
|
|
MX2020005182A
(es)
|
2017-11-22 |
2020-08-17 |
Inbiomotion Sl |
Tratamiento terapeutico del cancer de mama basado en el estado del c-maf.
|